摘要
目的了解CD4^＋CD25^＋FOXP3^＋T调节性T细胞在肝癌病人外周血中的表达水平并探讨其临床意义。方法应用流式细胞术测定18例肝癌病人外周血CD4^＋CD25^＋FOXP3^＋调节性T细胞占CD4^＋T淋巴细胞百分比，并与26例临床对照者和24例健康对照者进行比较。结果肝癌病人外周血中CD4^＋CD25^＋T细胞占CD4^＋T细胞百分比（4．25％±3．98％）明显高于临床对照组（1．34％±1．14％）及健康对照组（1．29％±0.95％）（P〈0．01），而两个对照组之间并无显著性差异（P〉0．05）。CD4^＋CD25^＋FOXP3^＋T细胞在肝癌病人外周血所占CD4^＋T细胞比率（2．94％±0．91％）也较临床对照组（0．76％±0．34％）及健康对照组（0．81％±0．29％）显著升高（P〈0．001），且升高幅度强于CD4^＋CD25^＋T细胞水平，两个对照组之间并无显著性差异（P〉0．05）。结论CD4^＋CD25^＋FOXP3^＋T细胞是更为准确的调节性T细胞，其在肝癌病人外周血中表达水平明显升高，检测CD4^＋CD25^＋FOXP3^＋T水平对肝癌的预防治疗具有重要临床意义。
Objective To determine the expression of CD4^＋ CD25^＋ FOXP3^＋ regulatory T cells （Treg ceils） in peripheral blood of patients with hepatocellular carcinoma （HCC） and investigate the clinical significance of Treg cells determination in clinical practice. Methods Flow cytometry was employed to measure the levels of CD4^＋ CD25^＋ T cells and CD4^＋ CD25^＋ FOXP3^＋ T ceils in peripheral blood of 18 HCC patients, 26 hospitalized patients without HCC （clinical control） as well as 24 healthy persons （healthy control）. Results The percentage of CD4^＋ CD25^＋ T cells in total CD4^＋ T cells isolated from the HCC patients（4.25%±3.98%） was elevated significantly compared to that in the clinical control group （1.34%±1.14%） or healthy control group （1.29%±0.95%） （both P〈0.01）. There was no difference in the percentage between the clinical control group and the healthy control group （P〉0.05）. Meanwhile, the ratio between CD4^＋ CD25^＋ FOXP3^＋ T cells and CD4^＋ T cells in HCC patients （2.94%±0.91%） also increased significantly compared to that in the clinical control group （0. 76%± 0.34%） or healthy control group （0.81%±0.29%） （both P〈0. 001）, which showed a more obvious increasing tendency than the ratio of CD4^＋ CD25^＋ T cells and CD4^＋ T cells. No difference in percentage of CD4^＋ CD25^＋ FOXP3^＋ T cells in CD4^＋ T cells was found between the clinical control group and the healthy control group （P〉0.05）. Conclusion As the more accurate regulatory T ceils, CD4^＋ CD25^＋ FOXP3^＋ T cells are able to detect the increase of population in HCC patients. Therefore, it is important to determine the levels of CD4^＋ CD25^＋ FOXP3^＋ T cells in HCC patients for prevention and treatment of malignancy.
出处
《中华肝胆外科杂志》
CAS
CSCD
北大核心
2010年第8期576-578,共3页
Chinese Journal of Hepatobiliary Surgery
关键词
癌
肝细胞
免疫治疗
淋巴细胞
T调节细胞
Carcinoma hepatocellular
Immunotherapy
Lymphocyte
Regulation T cell
